Login to Your Account

Tough Times Ahead for Public Biotechs in Need of Cash

By Catherine Hollingsworth

Monday, October 20, 2008
As investors remain skittish about the economy, financing options for cash-strapped, publicly traded biotech companies have dwindled. The outlook for the therapeutic biotech industry is somewhat brighter for venture-backed private biotech companies and public companies in a comfortable cash position, but many other biopharmaceutical companies are in a financial pinch. And until the economic turmoil stabilizes, there are few options for public traded biotechs looking to raise cash, industry sources told BioWorld Financial Watch.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription